Kalaris Therapeutics Inc (KLRS) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Kalaris Therapeutics Inc (KLRS) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $98.0M, listed on NASDAQ, employing roughly 14 people, carrying a beta of 0.15 to the broader market. Kalaris Therapeutics Inc operates as a pharmaceutical company. Led by Andrew Oxtoby, public since 2020-07-30.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for KLRS as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.